Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After the U.S. Food and Drug Administration approved Biogen (NASDAQ: BIIB ) Alzheimer’s drug, it fueled an uptrend for Cassava Sciences (NASDAQ: SAVA ). But in late July, buying euphoria capitulated. SAVA...
After three back-to-back sessions of losses, the healthcare stocks in the S&P 500 finished ~0.7% higher this week, underperforming the ~0.9% gain recorded by the broader index over the past five-day period. While developers focused on Alzheimer’s drugs made up l...
Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers. There was no correlation between the removal of amyloid plaques and cognitive function in the Biogen trial(s) in the highest ...
New York, New York--(Newsfile Corp. - August 2, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Annovis Bio, Inc. common stock (NYSE American: ANVS). Annovis is a clinical-drug company and its lead drug candidate is ANVS401 (a/k/a Posiphen...
Gainers: Ever-Glory International Group (NASDAQ:EVK) +122%. Infinity Pharmaceuticals (NASDAQ:INFI) +33%. Exicure (NASDAQ:XCUR) +34%. Xenetic Biosciences (NASDAQ:XBIO) +31%. Atlas Technical Consultants (NASDAQ:ATCX) +28%. Annovis Bio (NYSE:ANVS) +22%. Full Truck Alliance (NYSE:YMM) +21%. Allie...
NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ('Annovis') (NYSE:ANVS). On July 28, 2021, after the market closed, Ann...
Are These Former Penny Stocks On Your Watch List In August? Are penny stocks worth it? Take a look at some of the names and charts on this list and I’ll let you be the judge. Needless to say, where some penny stocks break out big in a single day or a few days, others go on to...
Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...
Annovis Bio forms part of an exclusive league of clinical-stage biotechs working on both Alzheimer's and Parkinson’s diseases. The stock's abruptly fluctuating path, influenced by results of clinical trials deserves to be analyzed. The analysis shows that much-publicized po...
Annovis shares sank by ~60% yesterday after the company presented additional data from a study of its lead drug Posiphen in 14 Alzheimer's and 14 Parkinson's patients. Promising data released in May had shown a 4.4 point increase in the cognitive scoring system ADAS-Cog11. Better than...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...